The Food and Drug Administration this week approved dexmedetomidine hydrochloride in 0.9% sodium chloride injection for the sedation of initially intubated and mechanically ventilated patients in an intensive-care setting and of non-intubated patients prior to and/or during surgical and other procedures.

The drug helps address short supplies of sedation options due to the COVID-19 public health emergency. Side effects of the drug include low blood pressure, slow heart rate and dry mouth.

Related News Articles

Perspective
We’ve been discussing for months how hospitals and health systems are contending with the worst financial crisis in their history as they continue to serve on…
Headline
The Centers for Medicare & Medicaid Services yesterday issued a final rule updating the home health prospective payment system for calendar year 2021.…
Headline
The Federal Reserve Board today reduced the minimum loan size for three Main Street Lending Program facilities from $250,000 to $100,000 and adjusted…
Headline
“The COVID-19 pandemic has proved that crisis tends to be a driver of innovation,” writes Jonathan Bandel, vice president of strategy and innovation for New…
Headline
The Food and Drug Administration Wednesday updated its guidance on enforcement policy for non-invasive remote monitoring devices that support patient…
Headline
Over 10,000 eligible nursing homes, or 76% of the field, will receive a portion of $333 million in COVID-19 Provider Relief Funds for meeting infection control…